SSRI augmentation could be considered. Small case series suggest that buspirone might be an effective augmentation agent at average doses of 50-60 mg/day, she said. Minimal data on antipsychotics to augment SSRI therapy mostly suggest that antipsychotics are not helpful, though some clinical experience hints at a possible role for atypicals.
Other augmenting agents that have shown some promise in limited reports include clomipramine, venlafaxine, lithium, and levetiracetam. Stimulants also have had positive results.
Dr. Phillips said she has received donated medications for studies from Forest Laboratories. She also reported receiving royalties from three publishers: The Free Press, Guilford Press, and Oxford University Press.